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Abstract: Three novel 5-(2-haloethyl)pyrimidine derivatives were synthesized and 
characterized by 1H-NMR, 13C-NMR, MS, IR spectra and elemental analysis. Iodine and 
chlorine atoms in the C-5 side chain were introduced by reaction of 5-(2-
hydroxyethyl)pyrimidine with hydroiodic acid and phosphoryl chloride, respectively. The 
structure of the intermediate α-(1-carbamyliminomethylene)-γ-butyrolactone was 
determined by X-ray crystal structure analysis. The molecule deviates very slightly from 
planarity. Three N−H···O hydrogen bonds link the molecules into one-dimensional chains 
of edge-fused rings. 
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Introduction 
A number of 5-substituted pyrimidine nucleoside analogues have been shown to have potent and 
selective cytotoxic activity in cells transfected with the HSV-1 TK gene [1-3]. The (E)-5-(2-
halovinyl)-2’-deoxyuridines are among the most potent and selective agents that undergo selective 
phosphorylation by the viral-encoded enzyme [4]. Pyrimidine nucleoside analogues, e.g. 5-(2-
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fluoroethyl)-2’-deoxyuridine, labelled with radioisotopes have applications in positron emission 
tomography (PET) to monitor the successful transfection of gene products in vivo during cancer-
prodrug therapy [5]. Recently, we have reported that some C-5 and/or C-6 substituted pyrimidine 
derivatives exhibited cytostatic activities against human tumor cell lines [6-11]. In view of the 
importance of 5-substituted uracil derivatives in cancer chemotherapy [12] and as antiviral agents [13-
15] we became interested in the synthesis of the novel 5-substituted uracils that we describe in this 
paper (Scheme 1). In addition, we also present herein the X-ray crystal structure of α-(1-
carbamyliminomethylene)-γ-butyrolactone, a precursor in the synthesis of these 5-substituted uracils. 
This compound, possessing two hydrogen-bonding donor groups and two acceptors, is very interesting 
from the supramolecular point of view, because it can form intricate hydrogen-bonded networks 
including chain motifs, rings, chains of rings and chains of edge-fused rings. 
 
Scheme 1. Synthesis of the 5-(2-haloethyl)pyrimidines 4-6. 
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Reagents and conditions: (i) NaOMe, ether, HCOOCH3, 24 h; (ii) urea, 3M HCl, 
4 °C, 24 h; (iii) NaOEt, ethanol, reflux, 6 h; (iv) HI, -5 °C, 90 min; (v) POCl3, 
reflux, 1h; (vi) NaOMe, reflux, 6 h. 
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Results and Discussion 
Synthesis 
The sodium derivative 1, prepared by reaction of γ-butyrolactone with methylformate in dry ether 
with the presence of sodium methoxide, was subsequently reacted with urea to give α-(1-
carbamyliminomethylene)-γ-butyrolactone (2) [16, 17]. Reaction of 2 with sodium ethoxide afforded 
5-(2-hydroxyethyl)uracil (3), which with 57% solution of hydroiodic acid gave 5-(2-iodoethyl)uracil 
(4). Chlorination of compound 3 with phosphoryl chloride afforded the chlorinated pyrimidine 
derivative 5, which was subsequently methoxylated giving 5-(2-chloroethyl)-2,4-dimethoxyuracil (6). 
The newly prepared compounds 4-6 were fully characterized by 1H- and 13C-NMR spectra, mass and 
IR spectra, as well as elemental analysis (see Experimental section). 
X-ray crystal structure study 
Compound 2 (Figure 1) consists of a carbamyliminomethylene moiety bonded to the butyrolactone 
ring. The whole molecule deviates very slightly from planarity, as the dihedral angle between the mean 
planes of the carbamyliminomethylene atoms N2/C7/O3/N1/C6 and butyrolactone ring atoms 
O1/O2/C2/C3/C4/C5 is 7.17(8)o. 
 
Figure 1. A molecular structure of 2, with the atom-numbering scheme. Displacement 
ellipsoids for nonhydrogen atoms are drawn at the 40 % probability level. 
 
 
 
A survey of the Cambridge Structural Database [18] (CSD; error-free and disorder-free structures of 
organic compounds with R<0.075) revealed 16 structures in which the carbon atom is double bonded 
to the butyrolactone ring (Figure 2, fragment I) and only one structure possessing a 
carbamyliminomethylene moiety [19] (Figure 2, fragment II).  
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Figure 2. Fragments from a Cambridge Structural Database survey. 
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The bond lengths and angles in 2 (Table 1) present no unexpected features and are within the ranges 
of equivalent ones in structures found in the CSD [18]. 
 
Table 1. Bond distances (Å) and bond angles (o) for 2. 
N1−C6 1.363(2) O3−C7 1.2251(19) 
N1−C7 1.3900(18) C2−C3 1.453(2) 
N2−C7 1.339(2) C3−C6 1.333(2) 
O1−C2 1.3417(17) C3−C4 1.495(2) 
O1−C5 1.450(2) C4−C5 1.518(2) 
O2−C2 1.2173(19)   
C6−N1−C7 121.43(13) C2−C3−C4 108.73(12) 
C2−O1−C5 110.77(12) C3−C4−C5 102.74(13) 
O2−C2−O1 120.86(14) O1−C5−C4 107.73(12) 
O2−C2−C3 129.10(15) C3−C6−N1 125.09(13) 
O1−C2−C3 110.02(12) O3−C7−N2 124.88(15) 
C6−C3−C2 121.18(13) O3−C7−N1 121.05(15) 
C6−C3−C4 130.00(14) N2−C7−N1 114.07(13) 
 
Table 2. Hydrogen-bonding geometry for 2. 
D−H···A D−H 
(Å)
H···A 
(Å)
D···A 
(Å)
D−H···
A 
N1−H1···O2i 0.85(2) 2.06(2) 2.869(2) 158(2) 
N2−H2A···O2i 0.90(2) 2.16(2) 2.974(2) 150(2) 
N2−H2B···O3ii 0.93(2) 1.96(2) 2.884(2) 174(2) 
Symmetry codes: (i) x, −1+y, z; (ii) 1−x, −1/2+y, 3/2−z. 
 
The carbamyliminomethylene moiety nitrogen atoms N1 and N2 and carbonyl oxygen atoms O2 
and O3 participate in the supramolecular assembly of 2. The N2 atom is a double proton donor and O2 
atom is a double proton acceptor (Table 2). 
The N1···O2i and N2···O2i intermolecular hydrogen bonds in 2 form a ( )6R12  [20] chain of rings 
parallel to the b axis (Figure 3). The N2···O3ii hydrogen bond links the molecules into C(4) chains that 
are also parallel to the b axis. The combination of these two motifs forms new ring of ( )14R33  type. 
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These three N−H···O hydrogen bonds generate mutually parallel one-dimensional chains of edge-
fused rings (Figure 3).  
 
Figure 3. A crystal packing diagram of 2, viewed along the a axis, showing  
chains of edge-fused rings formed by N−H···O hydrogen bonds. 
 
 
Figure 4. A crystal packing diagram of 2, viewed along the b axis, showing parallel chains 
of hydrogen-bonding molecules. 
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The crystal packing diagram along b axis (Figure 4) reveals that the hydrogen-bonded chains are 
parallel to the ( 2 , 0, 1). The distance between the planes passing through the center of the hydrogen-
bonded molecules is approximately 3.05 Å. Very similar one-dimensional hydrogen-bonded chains 
generate N−H···O hydrogen bonds in 1-carbamyliminomethylenetetrahydropyrrol-2-one [19]. 
 
Experimental Section 
 
General 
 
Melting points were determined on a Kofler micro hot-stage apparatus (Reichert, Wien) and are 
uncorrected. The electron impact mass spectra were recorded with an EXTREL FT MS 2002 
instrument with ionizing energy of 70 eV. 1H- and 13C-NMR spectra were recorded on a Bruker 
Avance 600 MHz spectrometer, operating at 600 MHz (1H) and 150.92 MHz (13C), respectively. The 
samples were dissolved in DMSO-d6 and measured in 5 mm NMR tubes. The 1H- and 13C-NMR 
chemical shift values (δ) are expressed in ppm referred to tetramethylsilane (TMS) and coupling 
constants (J) in Hz. The infrared spectra were recorded by a Fourier transform infrared (FTIR) 
spectrometer Bruker Vertex 70 equipped with an attenuated total reflection (ATR) accessory with a 
diamond crystal. Sixteen scans were collected for each measurement over the spectral range of 400-
4000 cm-1 with resolution of 4 cm-1. Precoated Merck Silica Gel 60F-254 plates were used for thin 
layer chromatography (TLC) and the spots were detected under UV light (254 nm). Column 
chromatography (CLC) was performed using silica gel (0.063-0.2 mm) Fluka; glass column was 
slurry-packed under gravity. Compound purity was analyzed by HPLC with DAD detector.  
 
Synthesis 
 
Sodium α-hydroxymethylene-γ-butyrolactone (1) [16]. To a cooled suspension of NaOMe (35.5 g, 0.66 
mol) in dry ether (650 mL), a solution of methylformate (52.6 mL, 0.85 mol) and γ-butyrolactone (50 
mL, 0.66 mol) was added dropwise. The stirring was continued at room temperature overnight. After 
cooling of reaction mixture the precipitated product 1 was filtered off and washed with dry ether (37.5 
g, 41.8 %, m.p. = 124 – 126 °C); MS m/z (EI) for C5H5NaO3 (M+•) calc. 136.0812; found 136.1; 1H-
NMR δ 8.46 (1H, s, H-1'), 4.24 (2H, t, J = 7.00 Hz, H-5), 2.44 (2H, dt, J = 9.97 Hz, 8 Hz, H-4); 13C-
NMR δ 176.96 (C-2), 166.54 (C-1'), 132.60 (C-3), 68.37 (C-5), 27.50 (C-4). 
  
α-(1-Carbamyliminomethylene)-γ-butyrolactone (2) [17]. To a solution of urea (30 g, 0.5 mol) in cold 
3M HCl (200 mL) was added sodium α-hydroxymethylene-γ-butyrolactone (1, 34 g, 0.25 mol). After 
stirring at 4 °C overnight the precipitated product was filtered off and washed with cold water. 
Recrystallization from water – ethanol gave white crystals of 2 (2 g, 5.2 %, m.p. = 246 – 247 °C); MS 
m/z (EI) for C6H8N2O3 (M+•) calc. 156.1394; found 156.1; 1H NMR δ 8.96 (1H, d, J = 11.71 Hz, NH), 
7.60 (1H, d, J = 11.97 Hz, H-1'), 6.38 (2H, s, NH2), 4.28 (2H, t, J = 7.5 Hz, H-5), 2.75 (2H, dt, J = 7.5 
Hz, 2.3 Hz, H-4); 13C-NMR δ 172.69 (C-3'), 154.35 (C-2), 132.60 (C-1'), 99.30 (C-3), 65.07 (C-5), 
24.19 (C-4).  
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5-(2-Hydroxyethyl)uracil (3). To a solution of NaOEt (0.277 g, 4 mmol) in ethanol (20 mL) was added 
α-(1-carbamyliminomethylene)-γ-butyrolactone (2, 1.7 g, 0.01 mol). Reaction mixture was refluxed 
for 6 h, during which time product precipitated. The solvent was removed under reduced pressure and 
the residue was dissolved in the water and acidified to pH = 3. The precipitated product 3 was filtered 
off, washed with ethanol and dried in vaccuo (1.55 g, 91.2 %); MS m/z (EI) for C6H8N2O3 (M+•) calc. 
156.1394; found 156.1; 1H-NMR δ 11.41 (1H, s, NH), 11.13 (1H, s, NH), 7.21 (1H, s, H-6), 3.63 (1H, 
t, J = 6.68 Hz, OH), 3.41 (2H, t, J = 6.62 Hz, H-2'), 2.29 (2H, t, J = 6.51 Hz, H-1'); 13C-NMR δ 164.32 
(C-4), 151.50 (C-2), 135.19 (C-6), 110.38 (C-5), 60.21 (C-2'), 29.06 (C-1'). 
 
5-(2-Iodoethyl)uracil (4). To a cooled solution of 3 (100 mg, 0.6 mmol) in H2O (10 mL), a solution of 
HI (57%, 1 mL) was added. The reaction mixture was stirred at -5 °C for 90 min, then solvent was 
evaporated and residue was purified by column chromatography (CH2Cl2:CH3OH = 60:1) to give oily 
product 4 (112 mg, 65 %); MS m/z (EI) for C6H7IN2O2 (M+•) calc. 266.0365; found 266; Anal. for 
C6H7IN2O2 calc. C 27.09 %, H 2.65 %, N 10.53 %; found C 27.13 %, H 2.64 %, N 10.55 %; IR: 3110–
2992 (ν N–H, CH2), 1720 (ν C=O), 1650–1420 (ν C=C and C–H ring), 1480 (δ CH2),  1022–770 (δ 
C=C–H, CH2), 940 (δ CH2–I), 520–480  (ν C–I) cm-1; 1H-NMR δ 10.97 (1H, s, NH), 10.62 (1H, s, 
NH), 7.20 (1H, s, H-6), 4.52 (2H, t, J = 5.4 Hz, H-2'), 2.28 (2H, t, J = 6.60 Hz, H-1'); 13C-NMR δ 
165.14 (C-4), 151.82 (C-2), 139.27 (C-6), 109.61 (C-5), 59.86 (C-2'), 20.03 (C-1'). 
 
5-(2-Chloroethyl)-2,4-dichloropyrimidine (5). The reaction mixture of 3 (600 mg, 4 mmol) and POCl3 
(17.7 mL, 0.19 mol) was refluxed for 1 h. Solvent was evaporated and ice was added in the residue 
which was then washed with ether and dried over Na2SO4. After drying the solvent was removed in 
vacuo and residue was purified by column chromatography (CH2Cl2:CH3OH = 30:1) which gave 
colourless oily product 5 (260 mg, 31%); MS m/z (EI) for C6H5Cl3N2 (M+•) calc. 211.4575; found 
211.5; Anal. for C6H5Cl3N2 calc. C 34.08 %, H 2.38 %, N 13.25 %; found C 34.01 %, H 2.39 %, N 
13.22 %; IR: 1633–1320 (ν C=C and C–H ring), 1430 (δs CH2), 1090 (δ CH2–Cl), 980-760 (δ C=C–H, 
CH2), 580–510 (ν C–Cl) cm-1; 1H-NMR δ 8.82 (1H, s, H-6), 3.93 (2H, t, J = 6.78 Hz, H-2'), 3.19 (2H, 
t, J = 6.78, H-1'); 13C-NMR δ 172.46 (C-4), 162.01 (C-2), 156.87 (C-6), 112.70 (C-5), 43.15 (C-2'), 
31.51 (C-1'). 
 
5-(2-Chloroethyl)-2,4-dimethoxypyrimidine (6). To a solution of NaOMe (120 mg, 2.2 mmol) in 
MeOH (15 mL) was added 5 (80 mg, 0.38 mmol), and the mixture was heated at reflux for 6 h. The 
solvent was evaporated, and H2O was added to dissolve NaCl. The oily layer was extracted with 
CH2Cl2, dried (Na2SO4), and concentrated under reduced pressure. The residue was purified by column 
chromatography (CH2Cl2:CH3OH = 30:1) which gave colourless oily product 6 (54 mg, 70.6 %); MS 
m/z (EI) for C8H11ClN2O2 (M+•) calc. 202.6379; found 202.6; Anal. C 7.42 %, H 5.47 %, N 13.82 %; 
found C 47.31 %, H 5.47 %, N 13.84 %; IR: 2960 (ν CH3), 1640–1330 (ν C=C and C–H ring), 1420 (δ 
CH2), 1210 (νas C–O–C), 1100 (δ CH2–Cl), 1050 (νs C–O–C), 905–760 (δ C=C–H, CH2), 630–520 (ν 
C–Cl) cm-1; 1H-NMR δ 8.19 (1H, s, H-6), 3.92 (3H, s, OCH3), 3.87 (3H, s, OCH3), 3.77 (2H, t, J = 
6.93 Hz, H-2'), 2.89 (2H, t, J = 6.93 Hz, H-1'); 13C-NMR δ 169.30 (C-4), 164.56 (C-2), 158.87 (C-6), 
111.44 (C-5), 54.85 (OCH3), 54.33 (OCH3), 43.75 (C-2'), 29.76 (C-1').  
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Crystal structure determination of 2 
A single crystal of 2 suitable for X-ray structure analysis was prepared by growth under slow 
evaporation at room temperature of a very dilute ethanol solution (v/v 96 %). The intensities were 
collected at 295 K on a Philips PW1100 diffractometer updated by Stoe and Cie [21, 22] using Mo-Kα  
radiation (0.71073 Å). Details of crystal data, data collection and refinement parameters are given in 
Table 3.  
Table 3. X-ray crystallographic data for 2. 
Formula C6H8N2O3 
Formula weight 156.14 
Crystal system monoclinic 
Space group P 21/c 
Unit cell dimensions  
a (Å) 7.0522(8) 
b (Å) 6.6691(6) 
c (Å) 15.1031(16) 
β (o) 94.869(9) 
V (Å3) 707.76(13) 
Z 4 
Dcalc. (g cm-3) 1.465 
Absorption coefficient μ (mm-1) 0.119 
F(000) 328 
θ range (°) 2.71 - 27.99 
Index ranges -9 ≤ h ≤ 9 
 -8 ≤ k ≤ 8 
 -11 ≤ l ≤ 19 
Collected reflections No. 2941 
Independent reflections No. / Rint. 1702 / 0.0231 
Reflections No. I ≥ 2σ(I) 1063 
Refined parameters No. 112 
Goodness-of-fit on F2, S 1.001 
R [I ≥ 2σ(I)] / R [all data] 0.0398 / 0.0783 
wR [I ≥ 2σ(I)] / wR [all data] 0.1061 / 0.1231 
Max./min. electron density (e Å-3) 0.189 / -0.141 
 
The structure was solved by direct methods [23]. All non-hydrogen atoms were refined 
anisotropically by full-matrix least-squares calculations based on F2 [23]. The hydrogen atoms bonded 
to nitrogen atoms were found in a difference Fourier map and their coordinates and isotropic thermal 
parameters have been refined freely. All other hydrogen atoms were included in calculated positions as 
riding atoms, with SHELXL97 [23] defaults. PLATON [24] program was used for structure analysis 
and molecular and crystal structure drawings preparation. CCDC 695308 contains the supplementary 
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crystallographic data for this paper. These data can be obtained free of charge via 
www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk, or by contacting 
The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 
1223 336033. 
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